Board of Directors

Cameron Durrant, MD

Lead Independent Director

Cameron Durrant is a pharmaceutical and biotech executive and entrepreneur. He trained and practiced medicine in Wales and Australia, before embarking on a pharmaceuticals career, initially with Merck and GSK in the UK, where he held sales, marketing and business development roles. He subsequently held staff and line international and US domestic responsibility for businesses at Pharmacia Corporation (until its acquisition by Pfizer) and Johnson and Johnson. He has been CEO/Chairman/CFO for four companies, two of which were public, one of which he founded and took public. He has been involved in five exits and raised over $50MM in investment funding. He has launched 20 brands, nationally, regionally and globally, including five which sold >$1Bn annually and one >$3Bn annually; three brands were nominated for Prix Galien awards. He was an Ernst + Young 'Entrepreneur of the Year' national finalist and named in the annual '100 Most Inspiring Leaders in Pharma' published by PharmaVoice on 3 separate occasions. Most recently, Cameron served as a corporate officer of Hi-Tech Pharmacal (recently sold to Akorn) and CEO of the ECR division (subsequently divested by Akorn to Valeant). Cameron earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, and his DipCH from the Melbourne Academy, Australia and his Master of Business Administration from Henley Management College, Oxford, UK. He is currently on the board of two private medical device companies and a founding board member of a private nanotech/oncology company.

Elliot Maza

Chief Executive Officer

Elliot Maza was appointed Chief Executive Officer of Immune Pharmaceuticals in September 2017, after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015. Previously he was Chairman, Chief Executive Officer and Chief Financial Officer at Intellect Neurosciences, Inc., Chief Executive Officer and Chief Financial Officer at Biozone Pharmaceuticals, Inc. and Chief Financial Officer at Emisphere Technologies Inc. Elliot was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. He began his professional career as an attorney at Sullivan and Cromwell in New York and then an investment banker in the Fixed Income divisions of Goldman Sachs & Co. and J.P. Morgan Securities, Inc., where he developed and marketed structured finance and derivative based transactions. Elliot has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. (inactive) in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.

Jeff Paley, MD


Dr. Jeff Paley has been an Active Clinician and Consultant in the healthcare industry for the past 19 years, during which time he has consulted for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Dr. Paley has also consulted for several biotechnology and specialty pharmaceutical companies, most notably in the areas of clinical development and business development and he has engineered transactions worth over $600 MM. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders, including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. He has served as a Director of Kellbenx and Retrophin and currently serves as a Director of Kalytera, Avenue Therapeutics and Remote Radiology Inc. Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital.

John Neczesny, MBA


Mr. Neczesny brings over 28 years of investment banking and corporate experience to this role. Mr. Neczesny is a Managing Partner at Blue Ox Healthcare Partners, LLC, a private investment firm providing capital to growth-stage healthcare companies. He was previously a Managing Director at Oberon Securities, LLC as an investment banker to healthcare companies and Vice President, Corporate Development at Par Pharmaceutical Companies. From 1998 to 2008, Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Prior to his corporate finance career, he spent 9 years in business development and project management roles in contract laboratory and data management businesses. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware.

Daniel Kazado


Daniel Kazado is a Senior Advisor to Melini Capital, a family owned private and public equity firm investing internationally in several industries. Melini Capital has been an early and significant investor in Immune Pharmaceuticals. Daniel built his own management consulting firm over 15 years to 25 professionals advising boards of directors and senior management in multiple industries, and in 2002 sold the company to Altran Technologies, a global engineering and management consulting group with revenues of over 1 billion. Daniel earned a bachelor's degree in Business Administration and a master's degree in Management from Lyon University in France.